Metabolic tumor burden is associated with major oncogenomic alterations and serum tumor markers in patients with resected pancreatic cancer.

@article{Shi2015MetabolicTB,
  title={Metabolic tumor burden is associated with major oncogenomic alterations and serum tumor markers in patients with resected pancreatic cancer.},
  author={Si Shi and Shunrong Ji and Yi Qin and Jin Xu and Bo Zhang and Wenyan Xu and Jiang Liu and Jiang Long and Chen Liu and Liang Liu and Quanxing Ni and Xianjun Yu},
  journal={Cancer letters},
  year={2015},
  volume={360 2},
  pages={227-33}
}
Pancreatic cancer is an aggressive and lethal disease with an overall 5-year survival rate of only 5%. Studies have demonstrated the ability of (18)F-fludrodeoxyglucose ((18)F-FDG) positron emission tomography/computed tomography (PET/CT) to measure the metabolic tumor burden in patients with various tumors, including pancreatic cancer. In a previous study, we investigated the predictive significance of the metabolic tumor burden in terms of the metabolic tumor volume (MTV) and total lesion… CONTINUE READING
Highly Cited
This paper has 145 citations. REVIEW CITATIONS
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-7 of 7 extracted citations

146 Citations

050100150201620172018
Citations per Year
Semantic Scholar estimates that this publication has 146 citations based on the available data.

See our FAQ for additional information.

Similar Papers

Loading similar papers…